Targeted Therapeutics for Cancer and Ophthalmology

Corporate Profile
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. We are a leader in the field of endoglin biology and are using our expertise to develop antibodies that bind to the endoglin receptor. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. Each of our product candidates is expected to complement currently available therapies.
Stock Quote
TCON (Common Stock)
Exchange:NASDAQ CM
$6.48 - 0.13 (1.82%)
Data as of 08/24/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
August 10, 2016
TRACON Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 3, 2016
TRACON to Report Second Quarter 2016 Company Highlights and Financial Results on August 10, 2016
June 6, 2016
TRACON Pharmaceuticals Announces Positive Results from TRC105 and TRC102 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever TRACON Pharmaceuticals Inc posts new information to the site. Just enter your email address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Print Page |
Email Page |
RSS Feeds |
Email Alerts |
Contact IR